<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>So far, reproducible histomorphologic and immunological criteria to distinguish clinicopathologic subtypes of blastic peripheral B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (BBCL), especially <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> (cb) and <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> (ib) <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, for daily diagnostic use are still lacking </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, we correlated the cytogenetic findings in 126 patients with BBCL with histopathologic diagnoses </plain></SENT>
<SENT sid="2" pm="."><plain>Subclassification of cb and ib <z:hpo ids='HP_0002665'>lymphomas</z:hpo> relied on the criteria defined in the updated Kiel classification; these subtypes are also listed in the Revised European-American <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> (REAL) classification and in a preliminary report on the newly established World Health Organization classification, to investigate their clinical significance </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, we performed a multivariate analysis to compare the prognostic significance of cytogenetic findings with the International Index </plain></SENT>
<SENT sid="4" pm="."><plain>There were significant differences in the frequency of chromosome aberrations between different BBCL subtypes: t(8;14) was predominantly present in Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, t(14;18) in <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, deletions in 8q and 14q, changes of 4q and losses of chromosome 10 in <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0002665'>lymphomas</z:hpo>; t(11;14) was restricted to blastoid mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and associated with a poor prognosis </plain></SENT>
<SENT sid="5" pm="."><plain>In cb <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, deletions in 1q42-qter, duplications in 1q23-32, <z:mp ids='MP_0004027'>trisomy</z:mp> 5, and changes of 15q were identified as independent prognostic factors </plain></SENT>
<SENT sid="6" pm="."><plain>In ib <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, changes of 7q and 8q had stronger impact on survival than the International Index </plain></SENT>
<SENT sid="7" pm="."><plain>These findings underline that Burkitt's, cb, ib, and blastoid mantle-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are biologically distinct and clinically relevant entities and that cytogenetic findings can be helpful to subtype BBCL </plain></SENT>
</text></document>